Semaglutide Sourcing After the Shortage: A Clinic Guide
Review FDA’s post-shortage semaglutide guidance, distinguish local backorders from federal shortage status, and identify questions for a clinic sourcing review.
For facility-specific purchasing requirements, visit our medical weight loss clinics sourcing guide. This article covers procurement, not treatment protocols.
Do not use an old shortage assumption
FDA determined the semaglutide injection shortage resolved in February 2025. Its April 1, 2026 update says semaglutide is not on the 503B bulks list or drug shortage list. Check the linked FDA updates before making a current sourcing decision.
Local shortages are a different question
A pharmacy or distributor being unable to fill an order does not put a drug back on the federal shortage list. Do not accept a local backorder as proof that shortage-based compounding exceptions apply.
Review the exact proposed pathway
Ask whether the proposal involves an FDA-approved product or a compounded preparation and identify the supplying entity. Patient-specific compounding and office stock have different conditions. A prescriber’s involvement does not remove all other requirements.
Avoid assumed workarounds
FDA explains restrictions on essentially copies and notes that combining semaglutide with another ingredient can still produce an essentially-copy preparation. FDA also warns about semaglutide salt forms. Have qualified reviewers assess the actual proposal rather than accepting “customized” as a sufficient explanation.
Request evidence before planning inventory
Record the exact ingredient, presentation, source, labeling, shipping requirements, and legal basis provided for the transaction. Compare approved purchasing requirements with the inventory guide linked below. This article does not advertise routine bulk-compounded semaglutide availability.
What to do next
Record unresolved questions and the evidence your clinical or quality reviewer needs before ordering. Use the medical weight loss clinics purchasing page to prepare a facility-specific inquiry. Product mentions do not confirm stock, a legal supply pathway, or suitability for patient care.
Regulatory sources and purchasing limits
Compounded drugs are not FDA-approved. Facility registration does not establish approval or eligibility for every preparation. Verify the exact product, source, applicable federal requirements, and state rules before ordering. This is procurement education, not medical or legal advice.
- FDA: bulk substances used under section 503B, including restrictions and interim policies.
- FDA: GLP-1 compounding and shortage updates.
- FDA: safety concerns for certain compounding substances.
FDA: concerns with unapproved GLP-1 drugs, including retatrutide and semaglutide salt forms.